BACKGROUND: The existing literature suggests that the surgical mortality (SM) observed with nephrectomy for localised disease varies from 0.6% to 3.6%. OBJECTIVE: To examine age- and stage-specific 30-d mortality (TDM) rates after partial or radical nephrectomy. DESIGN, SETTING, AND PARTICIPANTS: We relied on 24535 assessable patients from the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database. MEASUREMENTS: In 12283 patients, logistic regression models were used to develop a tool for pretreatment prediction of the probability of TDM according to individual patient and tumour characteristics. External validation was performed on 12252 patients. RESULTS AND LIMITATIONS: In the entire cohort of 24535 patients, 219 deaths occurred during the initial 30 d after nephrectomy (0.9% TDM rate). TDM increased with age (≤49 yr: 0.5% vs 50-59 yr: 0.7% vs 60-69 yr: 0.9% vs 70-79 yr: 1.2% vs ≥80 yr: 2.0%; χ(2) trend p<0.001) and stage (0.3% for T1-2N0M0 vs 1.3% for T3-4N0-2M0 vs 4.2% for T1-4N0-2M1; χ2 trend p=<0.001). TDM decreased in more recent years (1988-1993: 1.3% vs 1994-1998: 0.9% vs 1999-2002: 0.7% vs 2003-2004: 0.6%; χ2 trend p<0.001) and was lower after partial versus radical nephrectomy (RN) (0.4% vs 0.9%; p=0.008). Only age (p<0.001) and stage (p<0.001) achieved independent predictor status. The look-up table that relied on the regression coefficients of age and stage reached 79.4% accuracy in the external validation cohort. CONCLUSIONS: Age and stage are the foremost determinants of TDM after nephrectomy. Our model provides individual probabilities of TDM after nephrectomy, and its use should be highly encouraged during informed consent prior to planned nephrectomy.
BACKGROUND: The existing literature suggests that the surgical mortality (SM) observed with nephrectomy for localised disease varies from 0.6% to 3.6%. OBJECTIVE: To examine age- and stage-specific 30-d mortality (TDM) rates after partial or radical nephrectomy. DESIGN, SETTING, AND PARTICIPANTS: We relied on 24535 assessable patients from the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database. MEASUREMENTS: In 12283 patients, logistic regression models were used to develop a tool for pretreatment prediction of the probability of TDM according to individual patient and tumour characteristics. External validation was performed on 12252 patients. RESULTS AND LIMITATIONS: In the entire cohort of 24535 patients, 219 deaths occurred during the initial 30 d after nephrectomy (0.9% TDM rate). TDM increased with age (≤49 yr: 0.5% vs 50-59 yr: 0.7% vs 60-69 yr: 0.9% vs 70-79 yr: 1.2% vs ≥80 yr: 2.0%; χ(2) trend p<0.001) and stage (0.3% for T1-2N0M0 vs 1.3% for T3-4N0-2M0 vs 4.2% for T1-4N0-2M1; χ2 trend p=<0.001). TDM decreased in more recent years (1988-1993: 1.3% vs 1994-1998: 0.9% vs 1999-2002: 0.7% vs 2003-2004: 0.6%; χ2 trend p<0.001) and was lower after partial versus radical nephrectomy (RN) (0.4% vs 0.9%; p=0.008). Only age (p<0.001) and stage (p<0.001) achieved independent predictor status. The look-up table that relied on the regression coefficients of age and stage reached 79.4% accuracy in the external validation cohort. CONCLUSIONS: Age and stage are the foremost determinants of TDM after nephrectomy. Our model provides individual probabilities of TDM after nephrectomy, and its use should be highly encouraged during informed consent prior to planned nephrectomy.
Authors: Brian J Minnillo; William Tabayoyong; John J Francis; Matthew J Maurice; Hui Zhu; Simon Kim; Robert Abouassaly Journal: Can Urol Assoc J Date: 2017-05-09 Impact factor: 1.862
Authors: Andreas Becker; Marco Bianchi; Jens Hansen; Zhe Tian; Shahrokh F Shariat; Ioana Popa; Paul Perrotte; Quoc-Dien Trinh; Pierre I Karakiewicz; Maxine Sun Journal: World J Urol Date: 2014-02-11 Impact factor: 4.226
Authors: Marie C Hupe; Axel S Merseburger; Vinata B Lokeshwar; Hendrik Eggers; Hendrik Rott; Gerd Wegener; Mahmoud Abbas; Markus A Kuczyk; Thomas R Herrmann Journal: World J Urol Date: 2013-10-02 Impact factor: 4.226
Authors: Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Donald E Fry; Michael Pine; Susan M Nedza; David G Locke; Agnes M Reband; Gregory Pine Journal: Medicine (Baltimore) Date: 2016-09 Impact factor: 1.889
Authors: Naomi J Fulop; Angus I G Ramsay; Cecilia Vindrola-Padros; Michael Aitchison; Ruth J Boaden; Veronica Brinton; Caroline S Clarke; John Hines; Rachael M Hunter; Claire Levermore; Satish B Maddineni; Mariya Melnychuk; Caroline M Moore; Muntzer M Mughal; Catherine Perry; Kathy Pritchard-Jones; David C Shackley; Jonathan Vickers; Stephen Morris Journal: Implement Sci Date: 2016-11-25 Impact factor: 7.327
Authors: Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer Journal: Front Oncol Date: 2017-05-31 Impact factor: 6.244